Skip to main content

Table 1 Prevalence and cumulative incidence of HR-HPV, LR-HPV, and HR-HPV types among 3,731 women in the Costa Rican Vaccine Trial

From: A prospective study of absolute risk and determinants of human papillomavirus incidence among young women in Costa Rica

  % HPV positive at enrollment % HPV negative at enrollment % Cumulative HPV incidence#12 months % Cumulative HPV incidence 24 months % Cumulative HPV incidence end of follow-up^
HR-HPV 25.3 74.7 29.4 43.0 51.3
LR-HPV 21.8 78.2 31.7 47.4 54.3
HPV16 7.1 92.9 5.7 9.8 12.4
HPV18 2.5 97.5 3.5 6.3 8.2
HPV31 3.8 96.2 4.7 8.0 10.5
HPV33 1.0 99.0 1.7 3.1 3.8
HPV35 1.3 98.7 2.4 3.6 4.8
HPV39 3.2 96.8 3.7 6.1 8.3
HPV45 1.7 98.3 3.0 5.3 6.5
HPV51 4.2 95.8 6.1 10.8 13.6
HPV52 5.1 94.9 6.3 12.1 15.4
HPV56 3.2 96.8 4.0 7.5 9.8
HPV58 2.4 97.6 3.6 6.0 7.8
HPV59 1.3 98.7 2.4 4.9 6.3
  1. # Incidence defined by new detection of HPV type for women who were completely HPV negative at enrollment or who were positive only for other types.
  2. ^Average end of follow-up is 50.7 months, very few women had a maximum end of follow-up of 76 months.
  3. HR, High Risk; LR, Low Risk.